Early Achievement of 3- and 6-Month Treat-To-Target Goals After 4 Weeks of Abrocitinib Monotherapy in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis

*Affiliation at the time this study was conducted.

Jonathan I. Silverberg,¹ Eric L. Simpson,² Marjolein de Bruin-Weller,³ Stephan Weidinger,⁴ Peter Nilsson,⁵ Dan Henrohn,^{5*,6} Irina Lazariciu,⁷ William Romero,^{8*} Kris Jaho⁹ ¹The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; ²Oregon Health & Science University, Portland, OR, USA; ³National Expertise Centre for Atopic Dermatitis, University Medical Centre Utrecht, The Netherlands; ⁴University Hospital Schleswig-Holstein, Kiel, Germany; ⁵Pfizer AB, Stockholm, Sweden; ⁶Department of Medical Sciences, Uppsala University, Sweden; ⁶Pfizer AB, Stockholm, Sweden; ⁶Pfizer A

BACKGROUND

- A treat-to-target strategy proposed by experts for adults with moderate-to-severe atopic dermatitis (AD) suggests that treatment target goals at 3 months should be a \geq 1-point improvement in patient global assessment (PtGA) score and at least 1 of the following improvements¹:
- ≥50% in Eczema Area and Severity Index (EASI-50)
- $\geq 50\%$ in SCORing Atopic Dermatitis (SCORAD-50)
- ≥ 3 points in Peak Pruritus Numerical Rating Scale (PP-NRS3) $- \geq 4$ points in Dermatology Life Quality Index (DLQI4) $- \geq 4$ points in Patient-Oriented Eczema Measure (POEM4)
- At 6 months, the proposed treat-to-target goals are a PtGA score of ≤ 2 and at least 1 of the following¹: EASI-75 or EASI ≤7
- SCORAD-75 or SCORAD ≤24
- PP-NRS ≤4
- DLQI ≤5
- POEM ≤7
- Treatment continuation should be considered if the respective PtGA target goal plus at least 1 disease domain target goal is attained¹
- Findings from clinical trials indicate that treatment with abrocitinib, an oral, once-daily, Janus kinase 1-selective inhibitor, is associated with a rapid improvement in multiple clinical domains²
- A strong early response may be a predictor of a later response, as well as of treatment adherence

OBJECTIVES

- To estimate the proportions of patients with moderate-to-severe AD who attained 3-month and 6-month treat-to-target goals after only 4 weeks of abrocitinib monotherapy
- To assess itch relief at Week 4 of abrocitinib monotherapy

METHODS

Study Design

• Data were pooled from the JADE pivotal phase 3 clinical trials JADE MONO-1 (NCT03349060)³ and JADE MONO-2 (NCT03575871),⁴ in which patients with moderate-to-severe AD aged \geq 12 years were treated with abrocitinib (200 or 100 mg/day) or placebo (**Figure 1**)


Figure 1. JADE MONO-1 and JADE MONO-2 Study Design

Abrocitinib 100 mg QD **Eligibility Criteria** Adolescent and adult patients (≥12 years) with AD ≥1 year Abrocitinib Moderate-to-severe AD (IGA ≥3, EASI ≥16, %BSA affected ≥10, PP-NRS ≥4) 200 mg QD Inadequate response or intolerance to topical medication or requiring systemic therapy to control AD Placebo QD Time, weeks

%BSA, percentage of body surface area; AD, atopic dermatitis; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; PP-NRS, Peak Pruritus Numerical Rating Scale (with permission from Regeneron Pharmaceuticals, Inc., and Sanofi); QD, once daily.

Assessments and Statistical Analysis

- In this post hoc analysis, all randomized patients who received at least 1 dose of the study medication were assessed
- Assessments included:
- Proportions of patients attaining the 3- and 6-month treat-to-target goals at Week 4 • Only patients with available PtGA, EASI, PP-NRS, and DLQI data at Week 4 were included in this analysis
- Data are presented as observed and using descriptive statistics
- Least squares mean changes from baseline in PP-NRS score (with permission from Regeneron Pharmaceuticals, Inc., and Sanofi) were analyzed using a mixed-effects model with repeated measures



Data reported as observed; includes patients with available PtGA, EASI, PP-NRS, and DLQI scores at Week 4.


Presented at the National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo; October 6-9, 2024; Nashville, Tennessee

Abrocitinib 100 mg QD n=314	Abrocitinib 200 mg QD n=309
35 ± 16	33 ± 16
130 (41)	140 (45)
214 (68) 100 (32)	195 (63) 114 (37)
77 ± 20	75 ± 18
30 ± 12	30 ± 13
7 ± 2	7 ± 2
15 ± 7	15 ± 6

Itch Relief After 4 Weeks of Abrocitinib Treatment

abrocitinib 100 mg/day or placebo (**Figure 3**)

Figure 3. Changes in PP-NRS From Baseline to Week 4



LSM, least squares mean; MMRM, mixed-effects model with repeated measures; PP-NRS, Peak Pruritus Numerical Rating Scale. Mean PP-NRS \pm SD at baseline was 7 \pm 2 for all treatment arms. All randomized patients who received at least 1 dose of the study medication were assessed. MMRM contained fixed factors of treatment, week, treatment-by-week interaction, study, baseline disease severity, age category and baseline value and unstructured covariance matrix or compound symmetry covariance matrix.

CONCLUSIONS

REFERENCES

- 3. Simpson EL et al. *Lancet*. 2020;396:255-266.
- 4. Silverberg JI et al. JAMA Dermatol. 2020;156:863-873.

ACKNOWLEDGMENTS

The authors thank Pinaki Biswas for his assistance with the additional data analyses provided for this study. Editorial/medical writing support under the guidance of the authors was provided by Renata Cunha, PharmD, at ApotheCom, San Francisco, CA, USA, and was funded by Pfizer Inc., New York, NY, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med. 2022; 10.7326/M22-1460). This study was funded by Pfizer Inc.

Berlin, Germany.

CONTACT INFORMATION

Contact Kris Jaho at kris.jaho@pfizer.com for questions or comments.

• Greater improvements in PP-NRS change from baseline to Week 4 were observed with abrocitinib 200 mg/day than with

• As early as Week 4, a substantial proportion of patients treated with abrocitinib 200 mg or 100 mg monotherapy attained proposed 3-month and 6-month improvement goals in skin lesions, pruritus, and dermatology-related quality of life • Improvements in itch severity were greater with abrocitinib 200 mg and abrocitinib 100 mg than with placebo at Week 4 • These data suggest that abrocitinib treatment provides rapid relief of signs and symptoms across several clinical domains Moreover, currently proposed 3-month and 6-month treatment goals for patients with moderate-to-severe AD could be achieved far earlier with abrocitinib, thus enabling early clinical response assessment

1. De Bruin-Weller M et al. Acta Dermatol Venereol. 2021;101:1068. 2. De Bruin-Weller M et al. Br J Dermatol. 2022;186:e171. Abstract 684.

Previously presented at the Annual European Academy of Dermatology and Venereology (EADV) Congress; October 11-14, 2023;



Copies of this poster and the audio recording obtained through this QR code are for your own personal use only and may not be reproduced without permission from the authors.

Copyright © 2024. All rights reserved.